The post-infarcted related ventricular tachycardia (VT) is considered associated with increase in mortality or sudden cardiac death (SCD). Implantable cardioverter defibrillation (ICD) has been the standard therapy for the first or second prevention of SCD after myocardial infarction (MI). Incessant VT, which has poor response to anti-arrhythmic drugs and can cause repetitive ICD shock, is usually a tough problem in clinical practice. According to the guideline, incessant infracted related VT could be treated with catheter ablation.[@b1] Herein we reported a case of refractory scar-induced VT accompanied with thrombus in the left chamber, which was full with ups and downs during the therapy.

A 81-year-old male patient came to Drum Tower Hospital, Medical School of Nanjing University for "chest pain for nine years, palpitation for two years and recurrence for 12 h" on December 10^th^, 2018. Nine years ago, the patient was diagnosed acute anterior MI due to persistent chest pain. He accepted primary percutaneous coronary intervention and left anterior descending artery was deployed with 2 stents. The ultrasound demonstrated left ventricular end-diastolic diameter (LVDd) 6.66 cm, left ventricular ejection fraction (LVEF) 31%, ventricular aneurysm formed. The patient rejected ICD at that time. In February 2016, the patient came to us due to paroxymal palpitation. Electrocardiogram (ECG) showed monomorphic VT with heart rate (HR) of 156 bpm. VT discontinued after admistration of aminodarone. Then ICD was therefore implanted. Thereafter, the patient experienced appropriate ICD shocks intermittently which were proven by device programming. Nevertheless, the aminodarone was not prescribed due to long QT interval. On December 10^th^, 2018, the patient suffered palpitation and received shocks by ICD again. He also experienced syncope for about 30 s. Therefore, he was admitted in CCU. The patient had hypertension for 15years and prior ischemic stroke for half year, without drinking and smoking hobby.

The vital signs were stable. Temperature: 36.5°C, pulse rate: 55 beats per minute, breathing rate: 23 beats per minute, blood pressure: 113/62 mmHg. There was no distention of jugular vein, no rales in the lungs and no murmurs in the heart. The abdominal signs were negative. No edema in the lower extremities was seen. Laboratory tests were as follows: Troponin T 0.015 ug/L, brain natriuretic peptide 110 pg/mL, serum K^+^ 4.28 mmol/L. Blood routine test, hepatic function, renal function and coagulation function were nearly normal. ECG displayed monomorphic VT with HR of 148 bpm ([Figure 1A](#jgc-16-08-660-g001){ref-type="fig"}). The ultrasound revealed LVDd 6.7 cm, LVEF 32%, apex aneurysm formed and intraventricular thrombus was seen. Mitral valve and tricuspid valve were mild to moderate regurgitation. Aortic valve was mild regurgitation. The diagnosis was: (1) ventricular tachycardia; (2) prior myocardial infarction; (3) ischaemic cardiomyopathy; (4) hypertension; and (5) prior ischaemic stroke.

After admission, ICD programming identified the patient experienced episodic VT and ICD shocks before hospitalization. The monitor displayed sustained monomorphic VT and the blood pressure declined to 90/60 mmHg when VT occurred. Therefore, ICD programming was used to cease VT for several times. Particularly, antitachycardia pacing (ATP) was unable to terminate the VT, whereas ICD shock worked. Meanwhile, aminodarone was administrated in order to maintain the sinus rhythm ([Figure 1B](#jgc-16-08-660-g001){ref-type="fig"}) and rivaroxaban was used for anti-coagulation. However, VT recurred and sustained most of the time. There was definite indication of ventricular aneurysmectomy. But the patient rejected for fear of the procedural risks.

![The electrocardiogram evolution and catheter therapy during hospitalization.\
(A): Sustained VT with HR of 148 bpm when admission; (B): sinus rhythm with HR of 50 bpm after VT discontinued by implantable cardioverter defibrillation shock; (C): recurrence of VT with HR of 110 bpm when aminodarone has been used for three weeks; (D): sinus rhythm with ventricular pacing when aminodarone has been used for three weeks; (E): the septal branch near the apex (white arrow) was the target vessel for ASA; (F): the distal segment of the septal branch has occluded (white arrow) after ASA; and (G): the result of the endocardial mapping in the second radiofrequency ablation. The earliest activated location is the lateral wall above the apex. ASA: percutaneous coronary intervention; HR: heart rate; VT: ventricular tachycardia.](jgc-16-08-660-g001){#jgc-16-08-660-g001}

Radiofrequency ablation (RA) could not be performed for sake of intraventricular thrombus. We therefore performed alcohol septal ablation (ASA) on December 17^th^, 2018. In the procedure, angiography showed no severe stenosis in the coronary arteries. The OTW balloon was inserted into a septal branch near apex. After cold saline was injected, the VT stopped, then recurred quickly. Then 0.5 mL alcohol was injected into this branch and VT ceased immediately and did not recur in the procedure ([Figures 1E](#jgc-16-08-660-g001){ref-type="fig"} & [1F](#jgc-16-08-660-g001){ref-type="fig"}). However, VT came up again two hours after the therapy. We had to add nifekalant in combination with aminodarone as well as ICD programming to cease VT episodes. When the cumulative dosage of aminodarone went above 10 g, the VT still recurred and esmolol was also used to control the heart rate of VT. Approximate three weeks after hospitalization, the heart rate of VT was controlled between 108 bpm to 110 bpm ([Figure 1C](#jgc-16-08-660-g001){ref-type="fig"}). On January 2^nd^, 2019, the ultrasound was performed again. The thrombus disappeared fortunately. Thus, we performed RA on January 8^th^, 2019. But during the procedure, the index VT did not recur and programming stimulation induced two kinds of VT with different morphology, which were ablated together. On January 15^th^, 2019, we performed another RA when the aforementioned VT was persistent. By endocardial mapping, the target was located at the endocardium of the lateral wall just above the apex ([Figure 1G](#jgc-16-08-660-g001){ref-type="fig"}). VT terminated immediately after ablation. The sinus rhythm maintained with heart rate of 45 bpm ([Figure 1D](#jgc-16-08-660-g001){ref-type="fig"}). One week after second RA, VT recurred. This time, ATP programming terminated it successfully and VT did not come out anymore thereafter. The patient took aminodarone 200 mg once daily and metoprolol succinate SR 23.75 mg once daily for long-term.

Monomorphic VT was usually considered due to reentry mechanism. As regard to this patient, VT was associated with ventricular aneurysm. VT evolved progressively from non-sustained to sustained episodes although optimal pharmacological therapy has been given. Besides, the thrombus formed in the left chamber. As to this situation, ventricular aneurysmectomy was the first option.[@b2] However, the patient rejected open-heart surgery, which brought up a problem to us. All the measures according to the guideline,[@b3] including different anti-arrhythmic drugs, overdrive pacing and ICD shock were unable to inhibit the recurrent VT. Alcohol ablation was an alternative in case of intraventricular thrombus, which was the contraindication of RA. The advantage of ASA relies on the capability of preventing the recurrent VT not originating from endocardium, which could also not be approached from epicardium. It is commonly the rescue strategy after failure of RA as reported previously.[@b4],[@b5] In this case, the amount of alcohol injected was empirical, while the target branch selection was also empirical because we do not have the endocardial mapping result for focus orientation. These two limitations may be the main causes of VT recurrence after ASA. The RA was performed when we confirmed the thrombus dissolved. The recurrence incidence after ablation of infracted-related VT was about 7.9% within 30 days according to the registry data.[@b6] As to this patient, VT recurred one time after RA, which was ceased by ATP with 180 bpm easily and did not recur anymore thereafter. It was considered that the substrate modification by RA altered the myocardial electrophysiological characteristic, which made it feasible to stop VT by ATP. As the time passed, the scar formation after tissue edema may further prevent the recurrence of VT. However, the long-term efficacy for this patient needs to be identified during follow-up. We reflected that if the thrombus did not disappear in such short time, the patient should have to accept aneurysmectomy without any other options. Worse more, if the patient in this case had the contraindications of open-heart surgery or could not tolerate to the surgery, how should we do?
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